Liquid concentrates of calcium and magnesium
AssigneeBioLink Life Sciences, Inc.
InventorDeanna J. Nelson
Life of this patent
Estimating the term…
Abstract
The present invention relates to a liquid concentrate of calcium propionate and a magnesium salt, optionally with sweetener, taste-masking agent, flavoring, and thickening agent. Also provided is a method for binding phosphorus in ingesta, and inhibiting absorption of phosphorus from the gastrointestinal tract of a subject by administering to the subject a liquid concentrate of at least calcium salt and magnesium salt.
Claims21
A method for binding phosphorus within the gastrointestinal tract of a subject, comprising orally administering to said subject a liquid concentrate comprising:
- an aqueous solution of calcium propionate and a magnesium salt in a molar ratio of from 1.5:1 to 1:1.5, wherein the calcium propionate concentration in said aqueous solution is from 0.175 to 0.375 molar, the magnesium salt concentration in said aqueous solution is from 0.15 to 0.35 molar, the pH of said aqueous solution is in the range from pH 5 to pH 7.5, and said magnesium salt is selected from the group consisting of magnesium lactate, magnesium L-lactate, magnesium propionate, magnesium threonate, magnesium butyrate, and magnesium theanate.
A method for providing calcium and magnesium as a liquid concentrate, comprising dissolving calcium propionate and magnesium propionate in water to provide an aqueous solution wherein the calcium propionate concentration in said aqueous solution is from 0.175 to 0.375 molar and the magnesium propionate concentration in said aqueous solution is from 0.15 to 0.35 molar, the molar ratio of calcium propionate:magnesium propionate of from 1.5:1 to 1:1.5, and adjusting the pH of the resulting concentrate into the range from pH 5 to pH 7.5.
An aqueous solution for oral administration comprising calcium magnesium propionate, wherein the calcium magnesium propionate concentration in the said solution is from 0.175 to 0.375 molar, the pH of said solution is from pH 5 to pH 7.5, and the molar ratio of calcium to magnesium in said salt is in the range from 1:2 to 2:1.
A method for reducing the pill burden of a hyperphosphatemic subject, comprising orally administering to said subject a liquid concentrate comprising an aqueous solution of from about 1.5 to 3.5 mmol calcium magnesium propionate in each 5 mL of said aqueous solution, said aqueous solution having a pH of from 5 to 7.5.
A method for providing calcium and magnesium as a liquid concentrate, comprising dissolving calcium magnesium propionate in water to provide an aqueous solution comprising from 0.15 to 0.35 molar calcium magnesium propionate and adjusting the pH of the resulting concentrate into the range from pH 5 to pH 7.5.
An aqueous solution for oral administration comprising 1.5 to 3.5 mmol calcium magnesium propionate in each 5 mL of said aqueous solution, said aqueous solution having a pH of from 5 to 7.5.
21-23. (canceled)
Dependencies are inferred from the claim text.